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Abstract
Background: Several studies have demonstrated the predictive significance on survival of baseline quality of life
(QoL) in colorectal cancer (CRC) with little information on the impact of changes in QoL scores on prognosis in
CRC. We investigated whether changes in QoL during treatment could predict survival in CRC.
Methods: We evaluated 396 stages III-IV CRC patients available for a minimum follow-up of 3 months. QoL was
evaluated at baseline and after 3 months of treatment using EORTC QLQ-C30. Cox regression evaluated the
prognostic significance of baseline, 3-month and changes in QoL scores after adjusting for age, gender and stage
at diagnosis.
Results: After adjusting for covariates, every 10-point increase in both baseline appetite loss and global QoL score
was associated with a 7% increased risk of death with HR = 1.07 (95% CI, 1.01-1.14; P = 0.02) and (HR = 0.93 (95%
CI, 0.87-0.98; P = 0.01) respectively. A lower risk of death was associated with a 10-point improvement in physical
function at 3 months (HR, 0.86; 95% CI, 0.78-0.94; P = 0.001). Surprisingly, a higher risk of death was associated with
a 10-point improvement in social function at 3 months (HR, 1.08; 95% CI, 1.02-1.13; P = 0.008).
Conclusions: This study provides preliminary evidence to indicate that CRC patients whose physical function
improves within 3 months of treatment have a significantly increased probability of survival. These findings should
be used in clinical practice to systematically address QoL-related problems of CRC patients throughout their
treatment course.
Background
Quality of life (QoL) is a multidimensional construct. A
growing consensus among health care providers and
researchers is that treatment efficacy should be judged by
effects on both quantity and quality of life; this has led to
the inclusion of QoL assessment as a primary endpoint
in cancer clinical trials along with traditional endpoints
of tumor response and survival. There is general agree-
ment in the medical and scientific research community
that patients are the best source of information regarding
their QoL. Consequently, the use of self-reported QoL
assessment has become a valuable tool for both clinical
practice and research. There are extensive data in the
literature demonstrating that pretreatment/baseline QoL
can predict survival in several different types of cancers
independent of the extent of the disease and other clini-
cal prognostic factors [1-10], however, evidence is only
beginning to emerge regarding the prognostic signifi-
cance of changes in QoL scores in cancer [11-15].
Advanced stage colorectal cancer (CRC) is associated
with significant morbidity, which when coupled with the
adverse effects of cancer treatment, can further deterio-
rate patient QoL. A few studies have evaluated the rela-
tionship between pretreatment QoL and survival in CRC
[7,16-19]. However, to the best of our knowledge, there
is no study in the literature investigating the prognostic
significance of changes in QoL scores in CRC. In the
current study, we investigated whether pretreatment
QoL parameters as well as changes in QoL scores from
baseline until 3 months after treatment could predict
survival in patients with stages III-IV CRC. * Correspondence: gupta_digant@yahoo.com
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Study Population
We examined 396 histologically confirmed stages III and
IV colorectal cancer patients treated at Cancer Treat-
ment Centers of America
® at Midwestern (MRMC) and
Southwestern (SRMC) Regional Medical Centers
between January 2001 and December 2009. None of
these patients had received any treatment at our hospi-
tals when contacted to participate in this investigation.
The inclusion criteria for participation in this study
were a histological diagnosis of stage III or IV colorectal
cancer and the ability to read English. Patients were
excluded if they were unable to give informed consent
or were unable to understand or cooperate with study
conditions.
A trained clinical coordinator was responsible for deter-
mining eligibility, describing the study, and obtaining
informed consent. All patients were assured that refusal to
participate would not affect their future care in any way.
Patients who chose to participate were presented with the
QoL questionnaire at their initial/baseline visit and
instructed to return their completed questionnaires to the
clinical coordinator within 24 hours. Thus, patients com-
pleted baseline QoL questionnaires prior to receiving ther-
apy at our facility. Following the completion of the
baseline questionnaire, all patients were treated with an
integrative model combining surgery, radiation and che-
motherapy as appropriate, plus complementary therapy
consisting primarily of nutritional, psychosocial, and spiri-
tual support, naturopathic supplements, pain manage-
ment, and physical therapy/rehabilitation.
Additional data recorded for this study included age at
diagnosis, gender, stage of disease at diagnosis (III ver-
sus IV) and prior treatment history (previously treated
v e r s u sn e w l yd i a g n o s e d ) .T h eo n l yf o l l o w - u pi n f o r m a -
tion required was the date of death or the date of last
contact/last known to be alive, obtained from the tumor
registries at MRMC and SRMC. This study was
approved by the Institutional Review Board at Cancer
Treatment Centers of America
®.
QoL Assessment
QoL was assessed at baseline and after 3 months of treat-
ment using the European Organization for the Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30), which emphasizes a patient’s capacity
to fulfill the activities of daily living. The EORTC QLQ-
C30 is a 30-item cancer specific questionnaire that incor-
porates five functioning scales (physical, role, cognition,
emotional, and social), eight symptom scales (fatigue, pain,
and nausea/vomiting, dyspnea, insomnia, loss of appetite,
constipation, diarrhea, financial problems), financial well-
being scale and a global scale (based on two items: global
health and global QoL). The raw scores are linearly
transformed to give standard scores in the range of 0-100
for each of the functioning and symptom scales. Higher
scores in the global and functioning scales and lower
scores in the symptom scales indicate better QoL. A differ-
ence of 5-10 points in the scores represents a small
change, 10-20 points a moderate change and greater than
20 points a large, clinically significant change from the
patient’s perspective [20]. This instrument has been exten-
sively tested for reliability and validity [21-23].
Statistical Analysis
Patient survival was the primary end point and defined
a st h et i m ei n t e r v a lb e t w e e nt h ed a t eo ff i r s tp a t i e n t
visit to the hospital and the date of death from any
cause or the date of last contact/last known to be alive.
Two separate analyses were performed. First, the rela-
tionship between baseline QoL and patient survival was
investigated for 396 patients. Second, the relationship
between change in QoL scores between baseline and 3
months and survival was assessed for the same patient
cohort. Change scores were calculated by subtracting
baseline from 3-month QoL scores. The overall survival
was calculated using the Kaplan-Meier method. Clinical
and QoL variables were evaluated using univariate Cox
proportional hazards models to determine which para-
meters showed individual prognostic value for survival.
Multivariate Cox proportional hazards models were
then performed to evaluate the joint prognostic signifi-
cance of all QoL and clinical factors.
In order to minimize instability of the final multivari-
ate model resulting from high multicollinearity, global
QoL was evaluated separately because it is most highly
correlated with all other variables on the EORTC QLQ-
C30 questionnaire, and also because it is difficult to
interpret and manipulate clinically [24]. Each EORTC
QLQ-C30 scale was treated as a continuous variable for
the purpose of Cox regression analyses. The effect of
QoL parameters on patient survival was expressed as
hazard ratios (HRs) with 95% confidence intervals (CIs).
C h a n g e so f1 0o rm o r ep o i n t so na0t o 1 0 0s c a l ea r e
considered clinically relevant [20], so we present HRs
for a 10-point change on the continuous QoL variables.
An effect was considered to be statistically significant if
the p value was less than or equal to 0.05. All statistical
tests were two sided. All data were analyzed using SPSS
version 17.0 (SPSS, Chicago, IL, USA).
Cox regression with time-invariant covariates assumes
that the ratio of hazards for any two groups remains
constant in proportion over time. We checked this
assumption by first examining log-minus-log plots for
the categorical predictors and then fitting a Cox regres-
sion with a time-varying covariate for each predictor in
turn. Potential multicollinearity was assessed using mul-
tiple approaches. Large values (above 0.75) of Pearson’s
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pairs of QoL variables, with one member of the pair not
entered into the multivariate model (the measure that
was more meaningful or actionable was retained). As a
second check, the variance inflation factor (VIF) was
used with the final model to verify that multicollinearity
was not significantly influencing model coefficients
[25,26]. Finally, the possible influence of sample bias
and multicollinearity on the results was investigated
using a bootstrap re-sampling procedure. We generated
500 samples, each the same size as the original data set,
by random selection with replacement. Cox regression
was then run separately on these 500 samples to obtain
robust estimates of the standard errors of coefficients,
and hence the p values and confidence intervals of the
model coefficients [27].
Results
Patient Characteristics
Table 1 describes the baseline characteristics of our
patient cohort. At the time of this analysis, 211 deaths
had occurred among the 396 participants. Table 2
describes the results of univariate Cox regression analy-
sis for baseline patient characteristics. Stage at diagnosis
and prior treatment history were significantly associated
with survival while age at diagnosis and gender were
not. Median overall survival for the entire patient cohort
was 16.2 months (95% CI: 13.0-19.4 months). The med-
ian survival for newly diagnosed and previously treated
disease was 32.3 and 12.9 months respectively, p <
0.001. The median survival for patients with stage III
and stage IV disease was 16.9 and 15.8 months respec-
tively, p = 0.009.
Association between Baseline QoL and Survival
Table 3 describes the baseline scores for all dimensions
of EORTC QLQ-C30 instrument. Among the EORTC
QLQ-C30 functioning scales, social functioning had the
lowest (worst) mean score of 68.4 while the highest (best)
mean score of 79.7 was recorded for cognitive function-
ing. Among the EORTC QLQ-C30 symptom scales, nau-
sea/vomiting had the lowest (best) mean score of 13.4
while the highest (worst) mean score of 38.8 was
recorded for fatigue. Table 3 also displays the results of
univariate and multivariate Cox regression analyses for
each QoL variable. The HRs along with their 95% CIs for
every 10-point increase in all EORTC QLQ-C30 scales
are given. On univariate analysis, baseline QoL variables
that were predictive of survival were social function, dys-
pnea, loss of appetite, diarrhea and global health. Before
proceeding with multivariate analysis, we checked the
bivariate Pearson’s correlation among the QoL variables
to screen for observable multicollinearity. Role function
and fatigue were highly correlated (Pearson’s r = -0.80).
It was decided to retain fatigue and discard role function
in the multivariate model. This is because questions used
in the fatigue scale are more directly related to a patient’s
illness and physical condition than those used in the role
function scale. On multivariate analysis, only appetite
loss was found to be significantly associated with survival
such that every 10-point increase in baseline appetite loss
score was associated with a 7% increased risk of death
(HR, 1.07; 95% CI, 1.01 to 1.14; P = 0.02). In addition,
age, gender, stage at diagnosis and prior treatment his-
tory were all found to be statistically significant in the
multivariate model. A separate multivariate model was
run for global QoL after adjusting for age, gender, stage
and prior treatment history. It was found that every
10-point increase in baseline global QoL score was asso-
ciated with a 7% decreased risk of death (HR, 0.93; 95%
C I ,0 . 8 7t o0 . 9 8 ;P = 0.01). VIF values for baseline QoL
variables ranged from 1.1 (diarrhea) to 4.0 (fatigue), none
of which indicates a significant problem with
multicollinearity [25,26]. There was no evidence of non-
proportional hazards in the multivariate models
presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 3, we
conducted a bootstrap re-sampling procedure based on
500 samples. The bootstrap estimates of the multivariate
HRs along with corresponding p values and confidence
Table 1 Baseline characteristics of 396 colorectal cancer
patients
Characteristic Categories Number Percent
Age at Diagnosis (years) ■ Mean 53.2
■ Median 54
■ Range 23-83
Gender ■ Male 213 53.8
■ Female 183 46.2
Vital Status ■ Death 211 53.3
■ Alive 185 46.7
Treatment History ■ Newly diagnosed 120 30.3
■ Previously treated 276 69.7
Stage at Diagnosis ■ Stage III 176 44.4
■ Stage IV 220 55.6
Table 2 Baseline Characteristics and Associated HRs for
Death
Characteristic HR (95% CI) P
Age at Diagnosis (years) used as
continuous variable*
1.08 (0.94 - 1.21) 0.25
Gender (male as reference) 0.83 (0.63 - 1.1) 0.17
Treatment History (newly diagnosed as
reference)
2.6 (1.9 - 3.6) < 0.001*
Stage at Diagnosis (stage III as
reference)
1.4 (1.1 - 1.9) 0.009*
HRs correspond to a 10-point increment for age; *P < 0.05.
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p values for the coefficients for classical Cox regression
and bootstrap Cox regression led to the same conclu-
sion, except for the appetite loss scale, which although
significant in the classical model, became marginally sig-
nificant in the bootstrap model.
Association between Changes in QoL and Survival
Table 5 describes the change in scores from baseline to
3 months for all dimensions of EORTC QLQ-C30
i n s t r u m e n t .O na v e r a g e ,t h e yw e r es m a l l .T a b l e4a l s o
displays the results of univariate and multivariate Cox
regression analyses for change in QoL scores. On uni-
variate analysis, none of the change variables was signifi-
cantly predictive of survival. Before proceeding with
multivariate analysis, we checked the bivariate Pearson’s
correlation among the change scores to screen for
observable multicollinearity. Once again, change in role
function scores and change in fatigue scores were highly
correlated (Pearson’s r = -0.73). It was decided to retain
change in fatigue scores and discard change in role
function scores in the multivariate model for the same
reasons mentioned above. On multivariate analysis,
change variables that were significantly predictive of sur-
vival were physical function and social function. A lower
risk of death was associated with a 10-point improve-
ment in physical function at 3 months after treatment
(HR, 0.86; 95% CI, 0.78 to 0.94; P = 0.001). Surprisingly,
a higher risk of death was associated with a 10-point
improvement in social function at 3 months after treat-
ment (HR, 1.08; 95% CI, 1.02 to 1.13; P = 0.008). In
addition, age, stage at diagnosis and prior treatment his-
tory were found to be statistically significant in the mul-
tivariate model, while gender was not. A separate
multivariate model was run for change in global QoL
after adjusting for age, gender, stage and prior treatment
history, but change in global QoL was not a significant
predictor of survival. VIF values for change in QoL vari-
ables ranged from 1.1 (change in diarrhea) to 3.3
(change in fatigue), none of which indicates a significant
problem with multicollinearity. There was no evidence
of non-proportional hazards in the multivariate models
presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 5 as
well as the unexpected direction of association between
social function change and survival, we conducted a
bootstrap re-sampling procedure based on 500 samples.
The bootstrap estimates of the multivariate HRs along
Table 3 Baseline QoL Measures and Associated HRs for Death
Baseline Variable QoL Score Mean (SD) Univariate Multivariate
HR (95% CI) P HR (95% CI) P
General Quality of Life
Global 62.6 (24.0) 0.92 (0.87 - 0.98) 0.008* 0.93 (0.87 - 0.98) 0.01*
General Function
Physical 78.6 (20.7) 0.96 (0.89 - 1.02) 0.16 1.08 (0.97 - 1.20) 0.14
Role 70.3 (30.3) 0.97 (0.92 - 1.02) 0.21 Not used
Emotional 70.6 (22.7) 1.0 (0.94 - 1.06) 0.92 1.01 (0.92 - 1.09) 0.86
Cognitive 79.7 (22.0) 0.99 (0.94 - 1.05) 0.85 1.02 (0.93 - 1.12) 0.61
Social 68.4 (31.1) 0.96 (0.91 - 1.0) 0.04* 0.93 (0.86 - 1.01) 0.08
General Symptom
Fatigue 38.8 (27.9) 1.04 (0.99 - 1.08) 0.14 1.01 (0.90 - 1.11) 0.91
Nausea/Vomiting 13.4 (22.3) 0.99 (0.93 - 1.05) 0.84 0.95 (0.87 - 1.03) 0.18
Pain 29.3 (30.6) 1.03 (0.99 - 1.08) 0.12 1.02 (0.95 - 1.08) 0.64
Dyspnea 19.5 (26.2) 1.06 (1.01 - 1.11) 0.02* 1.05 (0.99 - 1.12) 0.09
Insomnia 33.7 (31.8) 1.03 (0.99 - 1.07) 0.17 1.04 (0.99 - 1.10) 0.12
Appetite Loss 25.2 (31.2) 1.05 (1.0 - 1.09) 0.03* 1.07 (1.01 - 1.14) 0.02*
Constipation 17.5 (27.4) 0.96 (0.91 - 1.02) 0.17 0.94 (0.88 - 1.00) 0.06
Diarrhea 15.4 (24.1) 1.07 (1.02 - 1.12) 0.01* 1.01 (0.95 - 1.07) 0.64
Financial 32.5 (32.9) 0.99 (0.95 - 1.03) 0.67 0.98 (0.92 - 1.03) 0.44
￿ HRs correspond to a 10-point increment for QoL scores.
￿ 2 sets of multivariate models were constructed: one for global QoL and other for all general function and symptom variables combined.
￿ Multivariate model (for general function and symptom variables combined) adjusted for age, gender, stage at diagnosis, prior treatment history and all baseline
QoL variables excepting role function.
￿ Multivariate model for global QoL adjusted for age, gender, stage at diagnosis and prior treatment history.
￿ *P < 0.05.
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provided in Table 6. We found no significant differences
in the coefficients p values between classical Cox regres-
sion and bootstrap Cox regression models. Physical
function and social function change variables which
were significant in the classical Cox model retained
their significance in the bootstrap Cox model as well.
Discussion
The current study was undertaken to investigate
whether baseline QoL as well as changes in QoL after 3
months of treatment could predict survival in stages III
and IV CRC. We chose EORTC QLQ-C30 as a valid
and a reliable tool to assess patient QoL. The EORTC
QLQ-C30 concentrates on a patients’ ability to fulfill the
activities of daily life justifying its use in clinical trials
investigating new drugs or novel combinations of agents.
Clinical practitioners and investigators need to know
what happens to a patient’s capacity to fulfill the activ-
ities of daily life at work and in the home. Consequently,
this instrument has an extensive physical functioning
scale coupled with a comprehensive symptom inventory.
There are three key findings of our study. First, appe-
tite loss and global health at baseline provides prognos-
tic information for survival after adjusting for the effects
of age, gender, treatment history, tumor stage and other
QoL variables. Second, improvement in physical func-
tion at 3 months is an indicator of improved patient
survival after adjusting for other covariates. Third, con-
trary to what one might predict, improvement in social
function at 3 months is independently associated with a
worse survival.
Our finding of improvement in physical function scores
correlating with better survival in CRC is consistent with
recent studies in esophagogastric and head and neck can-
cer patients (HNC) [11,13]. In patients with localized
HNC, Meyer F et al. found that at 1 year after treatment,
the HR associated with a positive physical function change
of 10 points was 0.75 (95% CI, 0.68 to 0.83). After physical
function was taken into account, no other QoL variable
was associated with survival [11]. In patients with esopha-
gogastric cancer, a 10-point change in physical function
(hazard ratio [HR], 0.85; 95% CI, 0.76 to 0.96; P = .007),
pain (HR, 1.20; 95% CI, 1.09 to 1.33; P < .001), and fatigue
(HR, 1.16; 95% CI, 1.04 to 1.30; P = .009) scores were each
associated with better survival [13].
An explanation for the unexpected association of an
increase in the social function scale score and decreased
patient survival cannot be elucidated from this study.
Multicollinearity does not seem to explain this counter-
intuitive finding. It is relevant to note, however, that the
two questions that comprise this scale query both the
effects of physical condition and medical treatment on
social function. Thus, both factors contribute to the
overall social function scale score but are expected to be
weighted differently at each assessment point for any
individual patient. Since this function is reported as a
single score, it is impossible to delineate the impact of
each factor on the change score. Nevertheless, it is rea-
sonable to speculate that change in the social function
score that is caused primarily by the effects of medical
treatment would be of lower prognostic value than
changes in physical condition. This hypothesis is testable
and worth further investigation. Our unexpected finding
regarding the social function scale stands in contrast
with the finding reported by Efficace et al. in advanced
CRC, where a 9% decrease in patient’s hazard of death
was found for any 10-point increase in the social func-
tioning score. In that study, social functioning was con-
cluded to be a prognostic measure of survival beyond a
number of previously known biomedical parameters
[28]. This finding was further validated in an indepen-
dent sample of metastatic CRC patients by the same
research group [18].
The results of this study have important implications
for both clinical and research practices. They suggest
Table 4 Bootstrap Multivariate HRs for Baseline QoL
Measures
Baseline Variable HR (95% CI) P
General Quality of Life
Global 0.93 (0.87 - 0.98) 0.01*
General Function
Physical 1.08 (0.97 - 1.22) 0.16
Role Not used
Emotional 1.01 (0.92 - 1.10) 0.86
Cognitive 1.02 (0.93 - 1.13) 0.57
Social 0.93 (0.83 - 1.02) 0.14
General Symptom
Fatigue 1.01 (0.90 - 1.10) 0.87
Nausea/Vomiting 0.95 (0.83 - 1.05) 0.30
Pain 1.02 (0.95 - 1.09) 0.69
Dyspnea 1.05 (0.99 - 1.13) 0.14
Insomnia 1.04 (0.99 - 1.12) 0.19
Appetite Loss 1.07 (1.0 - 1.16) 0.06
Constipation 0.94 (0.85 - 1.01) 0.08
Diarrhea 1.01 (0.94 - 1.09) 0.73
Financial 0.98 (0.91 - 1.05) 0.48
￿ HRs correspond to a 10-point increment for QoL scores.
￿ 2 sets of multivariate models were constructed: one for global QoL and
other for all general function and symptom variables combined.
￿ Multivariate model (for general function and symptom variables combined)
adjusted for age, gender, stage at diagnosis, prior treatment history and all
baseline QoL variables excepting role function.
￿ Multivariate model for global QoL adjusted for age, gender, stage at
diagnosis and prior treatment history.
￿ *P < 0.05.
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treatment and regular QoL assessment performed dur-
ing the course of treatment. Furthermore, interventions
aimed at improving specific QoL parameters should be
applied when indicated. The utility of this approach to
patient management, based on the findings described in
this study, would be validated definitively if interven-
tions that enhance specific QoL parameters are shown
to enhance survival.
Thus, the findings reported here suggest that QoL moni-
toring, coupled with treatment to improve appetite loss,
global health and physical function when indicated, should
be investigated in prospective studies in CRC. Positive
effects on survival as a consequence of interventions
designed specifically to improve patient symptoms and
QoL independent of tumor therapy would go a long way
towards establishing causative relationships between speci-
fic QoL parameters and disease control. Although some
progress has been made with respect to the treatment of
appetite loss and physical function in cancer patients, clin-
ical effectiveness is inconsistent and unpredictable. And
there are at present no effective means to address more
complex QoL factors such as global health. This chal-
lenges the cancer research enterprise to develop greater
understanding of the complex physiology responsible for
all aspects of QoL, and to use this information to develop
more effective and predictable methods to favorably mod-
ulate this critical aspect of patient health and wellness.
Several limitations of this study require careful
acknowledgment. Our study, because of its retrospective
nature, relies on data not collected to test a specific
hypothesis. As a result, we could not control for certain
factors in our analyses that could influence survival such
as treatment received at our institution, medical co-mor-
bidities, socioeconomic factors, support system, exercise
and educational level. The patient cohort was limited
only to those patients who were English speakers and
therefore is not representative of the complete spectrum
of colorectal cancer patients.M o r e o v e r ,t h i ss t u d yd o e s
not reveal a causative relationship between QoL and sur-
vival. Rather, patient QoL was found to act as a surrogate
for otherwise undetected prognostic factors [1]. QoL
scores were assessed over a three month interval only
which may not be sufficient time for score changes to
develop in other QoL parameters that may be prognostic
of survival. We did not control for the multiple compari-
sons made in this study, but this is acceptable for hypoth-
esis-generating studies [10].
Table 5 Change in QoL Measures and Associated HRs for Death
Change Variable QoL Change Mean (SD) Univariate Multivariate
HR (95% CI) P HR (95% CI) P
General Quality of Life
Global -1.8 (29.0) 1.00 (0.95 - 1.04) 0.93 0.99 (0.95 - 1.04) 0.81
General Function
Physical -2.0 (24.5) 0.96 (0.91 - 1.01) 0.14 0.86 (0.78 - 0.94) 0.001*
Role -3.1 (38.3) 1.02 (0.99 - 1.05) 0.25 Not used
Emotional 1.5 (28.9) 1.00 (0.96 - 1.04) 0.99 1.01 (0.95 - 1.07) 0.70
Cognitive -0.50 (27.9) 1.01 (0.96 - 1.05) 0.69 0.99 (0.92 - 1.06) 0.74
Social 0.84 (36.9) 1.03 (1.00 - 1.07) 0.08 1.08 (1.02 - 1.13) 0.008*
General Symptom
Fatigue 1.7 (34.3) 0.99 (0.95 - 1.02) 0.50 0.98 (0.90 - 1.05) 0.55
Nausea/Vomiting 2.0 (29.4) 1.01 (0.97 - 1.06) 0.61 1.03 (0.97 - 1.09) 0.39
Pain -1.6 (37.2) 1.00 (0.96 - 1.03) 0.95 1.01 (0.96 - 1.07) 0.68
Dyspnea 0.34 (32.4) 0.98 (0.94 - 1.02) 0.38 0.98 (0.93 - 1.03) 0.46
Insomnia 1.9 (40.8) 1.00 (0.97 - 1.04) 0.88 1.0 (0.95 - 1.04) 0.84
Appetite Loss 0.76 (37.9) 0.98 (0.95 - 1.02) 0.38 0.96 (0.91 - 1.01) 0.12
Constipation 0.25 (34.2) 1.02 (0.99 - 1.06) 0.19 1.02 (0.98 - 1.07) 0.29
Diarrhea 1.9 (33.7) 0.99 (0.94 - 1.03) 0.56 1.02 (0.98 - 1.07) 0.26
Financial 3.0 (39.9) 1.00 (0.97 - 1.04) 0.78 1.01 (0.97 - 1.04) 0.79
￿ HRs correspond to a 10-point increment for QoL scores.
￿ 2 sets of multivariate models were constructed: one for global QoL and other for all general function and symptom variables combined.
￿ Multivariate model (for change in general function and symptom variables combined) adjusted for age, gender, stage at diagnosis, prior treatment history and
all QoL change variables excepting role function change.
￿ Multivariate model for change in global QoL adjusted for age, gender, stage at diagnosis and prior treatment history.
￿ *P < 0.05.
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missing data on any EORTC QLQ-C30 variables for the
entire study sample; a homogeneous population of
patients with advanced CRC (stages III and IV) at pre-
sentation to our hospitals; the use of a valid and reliable
QoL instrument; the availability of clinical parameters in
nearly all patients; and availability of mature and reliable
survival data. As is the case for all exploratory retro-
spective studies, the most important outcome that can
be achieved is the development of a hypothesis sug-
gested by the results. As a consequence of this study, we
hypothesize that the parameters of physical function,
appetite loss, and global health are independent deter-
minants of survival in colorectal cancer, and should be
regularly assessed and when indicated, targeted for
intervention.
Conclusions
This exploratory study provides preliminary evidence to
indicate that CRC patients whose physical function
improves within 3 months of treatment have a signifi-
cantly increased probability of survival. These findings
should be used in clinical practice to systematically
address QoL-related problems of CRC patients through-
out their treatment course.
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